Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival

BACKGROUND: Anti-angiogenic treatment in recurrent glioblastoma patients suppresses contrast enhancement and reduces vasogenic edema while non-enhancing tumor progression is common. Thus, the importance of T2-weighted imaging is increasing. We therefore quantified T2 relaxation times, which are the...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Hattingen, Elke, Jurcoane, Alina, Daneshvar, Keivan, Pilatus, Ulrich, Mittelbronn, Michel, Steinbach, Joachim P., Bähr, Oliver
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2013
Konular:
Clinical Investigations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3779046/
https://ncbi.nlm.nih.gov/pubmed/23925453
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/not105
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller